Full Text:  <848>

Summary:  <238>

CLC number: 

On-line Access: 2023-03-10

Received: 2022-07-01

Revision Accepted: 2022-12-04

Crosschecked: 2023-03-13

Cited: 0

Clicked: 946

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Tianhe HUANG

https://orcid.org/0000-0002-2737-4016

Yongchang WEI

https://orcid.org/0000-0001-7205-4663

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B

Accepted manuscript available online (unedited version)


AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer


Author(s):  Yi LI, Wenyan SHE, Xiaoran XU, Yixin LIU, Xinyu WANG, Sheng TIAN, Shiyi LI, Miao WANG, Chaochao YU, Pan LIU, Tianhe HUANG, Yongchang WEI

Affiliation(s):  Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center & Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan 430071, China; more

Corresponding email(s):  weiyongchang@whu.edu.cn, zn004593@whu.edu.cn

Key Words:  N-‍(4-‍(1, 3, 2-dithiarsinan-2-yl)phenyl)acrylamide (AAZ2); Gastric cancer; Reactive oxygen species (ROS); Apoptosis; Pyruvate dehydrogenase kinase 1 (PDK1); Glucose metabolism


Share this article to: More <<< Previous Paper|Next Paper >>>

Yi LI, Wenyan SHE, Xiaoran XU, Yixin LIU, Xinyu WANG, Sheng TIAN, Shiyi LI, Miao WANG, Chaochao YU, Pan LIU, Tianhe HUANG, Yongchang WEI. AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2200351

@article{title="AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer",
author="Yi LI, Wenyan SHE, Xiaoran XU, Yixin LIU, Xinyu WANG, Sheng TIAN, Shiyi LI, Miao WANG, Chaochao YU, Pan LIU, Tianhe HUANG, Yongchang WEI",
journal="Journal of Zhejiang University Science B",
year="in press",
publisher="Zhejiang University Press & Springer",
doi="https://doi.org/10.1631/jzus.B2200351"
}

%0 Journal Article
%T AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer
%A Yi LI
%A Wenyan SHE
%A Xiaoran XU
%A Yixin LIU
%A Xinyu WANG
%A Sheng TIAN
%A Shiyi LI
%A Miao WANG
%A Chaochao YU
%A Pan LIU
%A Tianhe HUANG
%A Yongchang WEI
%J Journal of Zhejiang University SCIENCE B
%P 232-247
%@ 1673-1581
%D in press
%I Zhejiang University Press & Springer
doi="https://doi.org/10.1631/jzus.B2200351"

TY - JOUR
T1 - AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer
A1 - Yi LI
A1 - Wenyan SHE
A1 - Xiaoran XU
A1 - Yixin LIU
A1 - Xinyu WANG
A1 - Sheng TIAN
A1 - Shiyi LI
A1 - Miao WANG
A1 - Chaochao YU
A1 - Pan LIU
A1 - Tianhe HUANG
A1 - Yongchang WEI
J0 - Journal of Zhejiang University Science B
SP - 232
EP - 247
%@ 1673-1581
Y1 - in press
PB - Zhejiang University Press & Springer
ER -
doi="https://doi.org/10.1631/jzus.B2200351"


Abstract: 
Drastic surges in intracellular reactive oxygen species (ROS) induce cell apoptosis, while most chemotherapy drugs lead to the accumulation of ROS. Here, we constructed an organic compound, arsenical N-‍(4-(1,3,2-dithiarsinan-2-yl)phenyl)acrylamide (AAZ2), which could prompt the ROS to trigger mitochondrial-dependent apoptosis in gastric cancer (GC). Mechanistically, by targeting pyruvate dehydrogenase kinase 1 (PDK1), AAZ2 caused metabolism alteration and the imbalance of redox homeostasis, followed by the inhibition of phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway and leading to the activation of B-cell lymphoma 2 (Bcl2)/Bcl2-associated X (Bax)/caspase-9 (Cas9)/Cas3 cascades. Importantly, our in vivo data demonstrated that AAZ2 could inhibit the growth of GC xenograft. Overall, our data suggested that AAZ2 could contribute to metabolic abnormalities, leading to mitochondrial-dependent apoptosis by targeting PDK1 in GC.

AAZ2可通过靶向PDK1介导线粒体依赖的凋亡

李怡1, 佘文妍2, 徐笑然1, 刘艺欣1, 王新宇1, 田胜1, 李世毅1, 王淼1, 余超超3, 刘攀1, 黄天河1, 魏永长1
1武汉大学中南医院放化疗科, 湖北省肿瘤医学临床研究中心, 肿瘤生物学行为湖北省重点实验室, 中国武汉, 430071
2武汉大学化学与分子科学学院, 中国武汉, 430071
3武汉大学中南医院中西医结合科, 中国武汉, 430071
概要: 大部分化疗药物可以促进活性氧(ROS)产生,同时ROS可以诱导细胞凋亡。本研究构建了一种有机砷化合物N-(4-(1,3,2-dithiarsinan-2-yl)phenyl)acrylamide(AAZ2),其可通过促进ROS产生诱导胃癌线粒体依赖的细胞凋亡。具体机制为AAZ2通过靶向丙酮酸脱氢酶激酶1(PDK1)导致葡萄糖代谢改变和氧化应激,继而抑制PI3K/AKT/mTOR通路,最终激活半胱天冬酶(caspase)依赖的细胞凋亡。此外,体内实验也证实了AAZ2可以抑制胃癌移植瘤的生长。综上,在胃癌中,AAZ2可以通过靶向PDK1影响葡萄糖代谢及随后的氧化应激反应,抑制PI3K/AKT/mTOR信号通路,最终诱发线粒体依赖的细胞凋亡。

关键词组:AAZ2; 胃癌; 活性氧(ROS); 细胞凋亡; 丙酮酸脱氢酶激酶1(PDK1); 葡萄糖代谢

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]AnwarS, ShamsiA, MohammadT, et al., 2021. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy. Biochim Biophys Acta Rev Cancer, 1876(1):188568.

[2]CuiQB, WangJQ, AssarafYG, et al., 2018. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat, 41:1-25.

[3]D'SouzaLC, MishraS, ChakrabortyA, et al., 2020. Oxidative stress and cancer development: are noncoding RNAs the missing links? Antioxid Redox Signal, 33(17):1209-1229.

[4]ElliottMA, FordSJ, PrasadE, et al., 2012. Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial. Int J Pharm, 426(1-2):67-75.

[5]FattahiS, Amjadi-MohebF, TabaripourR, et al., 2020. PI3K/AKT/mTOR signaling in gastric cancer: epigenetics and beyond. Life Sci, 262:118513.

[6]García-GuerreroE, GötzR, DooseS, et al., 2021. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia, 35:201-214.

[7]GuHF, HuangTH, ShenYC, et al., 2018. Reactive oxygen species-mediated tumor microenvironment transformation: the mechanism of radioresistant gastric cancer. Oxid Med Cell Longev, 2018:5801209.

[8]HarrisIS, DeNicolaGM, 2020. The complex interplay between antioxidants and ROS in cancer. Trends Cell Biol, 30(6):440-451.

[9]HayesJD, Dinkova-KostovaAT, TewKD, 2020. Oxidative stress in cancer. Cancer Cell, 38(2):167-197.

[10]JinL, KimEY, ChungTW, et al., 2020. Hemistepsin A suppresses colorectal cancer growth through inhibiting pyruvate dehydrogenase kinase activity. Sci Rep, 10:21940.

[11]JoshiSS, BadgwellBD, 2021. Current treatment and recent progress in gastric cancer. CA Cancer J Clin, 71(3):264-279.

[12]LinJX, XieXS, WengXF, et al., 2019. UFM1 suppresses invasive activities of gastric cancer cells by attenuating the expression of PDK1 through PI3K/AKT signaling. J Exp Clin Cancer Res, 38:410.

[13]MissiroliS, PerroneM, GenoveseI, et al., 2020. Cancer metabolism and mitochondria: finding novel mechanisms to fight tumours. eBioMedicine, 59:102943.

[14]NerreterT, LetschertS, GötzR, et al., 2019. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat Commun, 10:3137.

[15]PaiS, YadavVK, KuoKT, et al., 2021. PDK1 inhibitor BX795 improves cisplatin and radio-efficacy in oral squamous cell carcinoma by downregulating the PDK1/CD47/Akt-mediated glycolysis signaling pathway. Int J Mol Sci, 22(21):11492.

[16]PerilloB, di DonatoM, PezoneA, et al., 2020. ROS in cancer therapy: the bright side of the moon. Exp Mol Med, 52(2):192-203.

[17]SanzMA, FenauxP, TallmanMS, et al., 2019. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 133(15):1630-1643.

[18]Škorja MilićN, DolinarK, MišK, et al., 2021. Suppression of pyruvate dehydrogenase kinase by dichloroacetate in cancer and skeletal muscle cells is isoform specific and partially independent of HIF-‍1α. Int J Mol Sci, 22(16):8610.

[19]SmythEC, NilssonM, GrabschHI, et al., 2020. Gastric cancer. Lancet, 396(10251):635-648.

[20]SradhanjaliS, TripathyD, RathS, et al., 2017. Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: a potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions. PLoS ONE, 12(5):e0177744.

[21]SchneiderCA, RasbandWS, EliceiriKW, 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods, 9(7):671-675.

[22]ShangMT, ZhouZW, KuangWB, et al., 2021. High-precision 3D drift correction with differential phase contrast images. Opt Express, 29(21):34641-34655.

[23]TataranniT, PiccoliC, 2019. Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxid Med Cell Longev, 2019:8201079.

[24]TewariD, PatniP, BishayeeA, et al., 2022. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol, 80:1-17.

[25]VelpulaKK, BhasinA, AsuthkarS, et al., 2013. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res, 73(24):7277-7289.

[26]WadgaonkarP, ChenF, 2021. Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis. Semin Cancer Biol, 76:258-266.

[27]WangP, JinJM, LiangXH, et al., 2022. Helichrysetin inhibits gastric cancer growth by targeting c-Myc/PDHK1 axis-mediated energy metabolism reprogramming. Acta Pharmacol Sin, 43(6):1581-1593.

[28]WangQQ, JiangY, NaranmanduraH, 2020. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. Metallomics, 12(3):326-336.

[29]WangWP, DongXX, LiuY, et al., 2020. Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways. Biomed Pharmacother, 131:110661.

[30]WengMS, ChangJH, HungWY, et al., 2018. The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. J Exp Clin Cancer Res, 37:61.

[31]WuJ, HendersonC, FeunL, et al., 2010. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs, 28(5):670-676.

[32]XuXH, WangHB, LiHY, et al., 2019. S-Dimethylarsino-glutathione (darinaparsin®) targets histone H3.3, leading to TRAIL-induced apoptosis in leukemia cells. Chem Commun, 55(87):13120-13123.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE